Research programme: neurodegenerative diseases gene therapies - Locanabio
Alternative Names: CORRECTx RNA-targeting gene therapyLatest Information Update: 23 May 2023
At a glance
- Originator Locanabio
- Class Gene therapies; Neuroprotectants
- Mechanism of Action Gene modulators; RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- Research Frontotemporal dementia; Huntington's disease; Spinocerebellar ataxias
Most Recent Events
- 16 May 2023 Pharmacodynamics data from a preclinical trials in amyotrophic lateral sclerosis released by Locanabio
- 19 May 2022 Pharmacodynamics data from a preclinical trials in amyotrophic lateral sclerosis released by Locanabio
- 01 May 2022 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral)